Personalized neoantigen cancer vaccines in the spotlight

Neoantigens—mutated peptides arising from somatic changes specific to tumor cells—represent a unique class of immunogenic targets. These non-self-antigens can stimulate potent anti-tumor responses due to their high affinity for T cells and absence of central tolerance, unlike tumor-associated antigens. In this review, we discuss potential of neoantigens as vaccine targets, the advantages of a vaccine approach targeting personalized neoantigens, and the challenges of neoantigen identification and selection. Updates on current neoantigen-based vaccine platforms and clinical trial outcomes are summarized. The emerging synergy between personalized neoantigen vaccines and immune checkpoint inhibitors is highlighted. Future directions and challenges in neoantigen vaccine development are also discussed.

Please enter your email to access content Read now